Workflow
Cibus(CBUS)
icon
Search documents
Cibus(CBUS) - 2024 Q2 - Earnings Call Transcript
2024-08-10 15:19
Cibus, Inc. (NASDAQ:CBUS) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Wade King - Chief Financial Officer Rory Riggs - Co-Founder, Chairman and CEO Peter Beetham - Co-Founder, President and COO Conference Call Participants Nick Anderson - ROTH Capital Matthew Venezia - Alliance Global Partners Austin Moeller - Canaccord Sameer Joshi - H.C. Wainwright Steve Byrne - Bank of America Operator I’d like to turn the conference over to Wade King, Chief Financial Officer. Sir, ple ...
Cibus (CBUS) Reports Q2 Loss, Tops Revenue Estimates
ZACKS· 2024-08-08 23:11
Cibus (CBUS) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $0.81. This compares to loss of $3.05 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -40.74%. A quarter ago, it was expected that this developer and licensor of plant traits for seed companies would post a loss of $1.01 per share when it actually produced a loss of $1.12, delivering a surprise of -10.89%. Over the ...
Cibus(CBUS) - 2024 Q2 - Quarterly Report
2024-08-08 20:32
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ _____________________ _____________________ FORM 10-Q (Mark One) xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024; or oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_________to_________ Commission file number 001-38161 | --- | --- | |-------------------------- ...
Cibus(CBUS) - 2024 Q2 - Quarterly Results
2024-08-08 20:09
Cibus Reports Second Quarter Financial Results and Provides First Half Business Update Demonstrated continued momentum securing an agreement for its Herbicide Tolerance (HT) traits in Rice with a fourth customer in the second quarter with signing of agreement with Federacion Nacional de Arroceros ("FEDEARROZ"); builds on prior agreements with Loveland Products, Inc., a subsidiary of Nutrien, Ltd., in the United States and with Interoc S.A. in Latin America Rice platform is the Company's first entry into the ...
Cibus Achieves Positive Initial Field Trial Results for Stacked Gene Edited Herbicide Tolerant Traits in Rice
Newsfilter· 2024-08-06 11:36
Early results of a novel weed management solution using two herbicides show promise. The first known use of stacked gene edited herbicide tolerant traits in an elite variety of rice to improve weed management. SAN DIEGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced that it has positive initial field trial results of a novel weed management solution for rice farm ...
Cibus Achieves Positive Initial Field Trial Results for Stacked Gene Edited Herbicide Tolerant Traits in Rice
GlobeNewswire News Room· 2024-08-06 11:36
Early results of a novel weed management solution using two herbicides show promise. The first known use of stacked gene edited herbicide tolerant traits in an elite variety of rice to improve weed management. SAN DIEGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced that it has positive initial field trial results of a novel weed management solution for rice farm ...
Cibus to Report Second Quarter 2024 Financial Results on August 8, 2024 After the Market Close and Host Conference Call
GlobeNewswire News Room· 2024-08-01 11:00
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced that the company will report second quarter 2024 financial results on Thursday, August 8, 2024. Cibus' management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates. Title: Cibus, Inc. Second Quarter 2024 Results Conferen ...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cibus, Inc. - CBUS\
Prnewswire· 2024-07-02 15:15
NEW YORK, July 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cibus, Inc. ("Cibus" or the "Company") (NASDAQ: CBUS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. On June 4, 2024, Bonitas Research ("Bonitas") issued a report alleging that it had "found no evidence that Cibus' gene-editing technology brings desirable new crops to market." Bonitas asserted that it had found "farmer complaints of lower crop yields ...
Cibus Expands its Intellectual Property Coverage for Plant Gene Editing and Traits
Newsfilter· 2024-06-26 12:30
Additional patents issued for 10 plant trait and editing families in the past two quarters. SAN DIEGO, June 26, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced that it has expanded its intellectual property coverage for 10 gene editing and trait families. This intellectual property expansion over the last 6 months covers several areas including gene editing, productivity tr ...
Cibus Expands its Intellectual Property Coverage for Plant Gene Editing and Traits
GlobeNewswire News Room· 2024-06-26 12:30
Cibus is a leader in the development of complex gene edited traits in plants like Pod Shatter Reduction in Canola and Herbicide Tolerance in Rice. The Company's plant trait intellectual property is developed using its Rapid Trait Development System (RTDS®) including Gene Repair Oligonucleotides (GRON) and Transcription activator-like effector nuclease (TALEN) technology. About Cibus without limitation, market conditions, failure to satisfy customary closing conditions and the risk factors and other matters ...